Antibody-drug conjugates (ADCs) refer to a new class of biotherapeutic drugs manufactured by conjugating monoclonal antibodies and small molecule cytotoxic drugs by linkers. Compared with traditional cytotoxic drugs, ADC has the advantages of strong targeting and less toxic side effects. Among them, antibodies can accurately deliver small molecule cytotoxic drugs to the tumor site by binding to the targeted antigens on the surface of tumor cells to achieve the tumor-specific killing effect. ADC drugs are emerging as a hot field of competition for antitumor drug research and development in recent 2 years.

SY-ADC Products Library is the latest series of products launched by Sanyou Bio based on our 8 years of production experience. Capable of all processes from protein production to quality management, Sanyou Bio can provide clients with customized full-process services using automated equipment and digital management. By now, the annual throughput of proteins has reached 100,000+, which can guarantee a stable supply of all types of products. Also, 24/7 Customer Service will solve all customer concerns.

As an important part of ADC development and manufacturing processes, ADCs have a wide range of applications in efficacy validation, pre-toxicology experiments, and quality control. With unique integrated ADC manufacturing platform, Sanyou Bio can formulate customized manufacturing plans according to sample characteristics, and provides customers with high-quality ADCs through head-to-head comparisons with the original drug.

As an important backbone of ADC drugs, ADC antibodies are involved in multiple R&D steps, such as activity quality control, antibody production, and in vitro and in vivo efficacy validations. Using 4 cell lines (CHO) with international licenses, in combination with GMP-grade raw materials, a class C+A clean environment, and a complete quality control system, Sanyou Bio ensures the production of high quality ADC antibodies.

As the starting point of ADC R&D, ADC antigens are involved in multiple R&D steps, such as activity quality control, antibody production, and in vitro and in vivo efficacy validations. With our high-throughput automated protein production platform and Alphafold2 structure analysis platform, Sanyou Bio can optimize antigen design according to protein structure, customize protocols according to sample characteristics, and combine a variety of expression systems, purification plans, and quality control criteria, to complete multi-dimensional, efficiently optimized sample preparation and produce proteins closer to natural conformations for customers.

ADC linkers, as "ties" between ADC antibodies and small cytotoxic drugs, are in high demand in ADC conjugation. Sanyou Bio can provide a range of traditional linkers, including chemically cleavable linkers, enzymatically cleavable linkers, thioether linkers, maleimido caproyl linkers, and so on, to provide customers with more diverse choices.

ADC cytotoxin, the toxin effector component in ADC drugs, is in high demand in ADC conjugation. Sanyou Bio can provide customers with multiple types and categories of classical toxins, such as topoisomerase inhibitors and microtubule inhibitors, to facilitate personalized selection.

As important carriers for cell-level efficacy assessment, ADC overexpression cell lines can be used in all steps of ADC R&D. To meet needs of customers, Sanyou Bio has developed a series of high-quality ADC overexpression cell line and functional cell line products, all of which have been well validated in stability and can be used in early drug discovery, functional validation, and CMC quality control release, providing a stable and convenient tool for new drug research and development.